期刊文献+

小剂量奥沙利铂化疗对小鼠H22肝癌乏氧的影响 被引量:2

The influence of low dose oxaliplatin chemotherapy on hypoxia in mouse H22 liver cancer
下载PDF
导出
摘要 目的观察小剂量奥沙利铂化疗对小鼠H22肝癌乏氧动态变化的影响,并探讨乏氧改变与其抗血管生成效应的关系。方法建立小鼠H22肝癌皮下移植瘤模型,将成瘤小鼠随机分成对照组(5%葡萄糖20ml/kg)和治疗组(奥沙利铂1.5mg/kg),分别隔日腹腔给药(设为d0、d2、d4、d6)。于d1、d3、d5、d7行99mTc-HL91乏氧显像,在平面图像上通过核医学感兴趣区(ROI)技术,计算肿瘤与对侧相应部位放射性比值(T/NT)。两组于d1、d3、d5、d7分别处死小鼠,取瘤体,免疫组织化学染色检测肿瘤组织中CD34表达,连续观察d1、d3、d5、d7治疗组与对照组血管形态差异,并比较肿瘤微血管密度(MVD)的动态变化。结果对照组d1、d3、d5、d7T/NT比值分别为3.416±0.264、3.883±0.346、4.105±0.371和4.439±0.428,治疗组d1、d3、d5、d7T/NT比值分别为3.369±0.100、2.195±0.106、3.367±0.214和4.262±0.214,治疗组d3T/NT最低。对照组d1、d3、d5、d7MVD分别为30.17±1.17、33.50±1.05、37.50±1.05和40.83±1.47,治疗组d1、d3、d5、d7MVD分别为28.83±1.47、23.07±1.47、20.17±1.94和18.33±1.21。结论小剂量奥沙利铂化疗能够一过性改善乏氧,并与其抗血管生成作用一致,有可能增强肝癌放疗的疗效。 Objective To observe the influence of low dose oxaliplatin chemotherapy on dynamic oxygenation change within tumors and explore the relation between hypoxia and antiangiogenic effect.Methods Mouse tumor model was established by implanting H22 mouse hepatocarcinoma cells under skin.Experimental mice were randomly divided into two groups,including control group(5% glucose intraperitoneal injection,20ml/kg) and treatment group(1.5mg/kg oxaliplatin).Drug was given on d0,d2,d4 and d6.Tumors were imaged using 99mTc-HL91 technique on d1,d3,d5,d7 and the radioactivity ratio of tumor to normal tissue(T/NT) were calculated using the region-interesting(ROI)technique.Mice from 2 group were killed and taken tumor tissues on d1,d3,d5,d7.The expression of CD34 was detected using immunohistochemistry staining method,by which to observe continuous disparities of vessel morphous and compare dynamic changes of microvessel density.Results The ratio of T/NT in control group were 3.416±0.264,3.883±0.346,4.105±0.371 and 4.439±0.428 on d1,d3,d5,d7,and in treatment group were 3.369±0.100,2.195±0.106,3.367±0.214 and 4.262±0.214,respectively.The MVD were 30.17±1.17,33.50±1.05,37.50±1.05 and 40.83±1.47 in control group and were 28.83±1.47,23.07±1.47,20.17±1.94 and 18.33±1.21 in treatment group.Conclusion Low dose oxaliplatin chemotherapy could improve hypoxia transiently,which accord with its antiangiogenic action.We assume its possibly normalization effect of tumor vasculature,thus further improve hypoxia,which was vital to enhance effect of radiotherapy and chemotherapy.
出处 《临床肿瘤学杂志》 CAS 2011年第5期407-411,共5页 Chinese Clinical Oncology
基金 南京市卫生局重点项目(ZKX09017)
关键词 抗血管生成 化学治疗 乏氧 奥沙利铂 H22肝癌细胞 Antiagniogenesis Chemotherapy Hypoxia Oxaliplatin H22 hepatocarcinoma cell line
  • 相关文献

参考文献5

  • 1Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice[J]. J Clin Invest, 2000,105(8) :1045 -1047.
  • 2Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer [ J ]. Cancer Res, 2000,60 ( 7 ) : 1878 - 1886.
  • 3Tong RT,Boucher Y,Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors[ J ]. Cancer Res, 2004,64 ( 11 ) :3731 - 3736.
  • 4Dickson PV,Hamner JB,Sims TL, et al. Revacizumab-induced transient remodeling of the vaseulature in neuroblastoma xeno- grafts results in improved delivery and efficacy of systemically administered chemotherapy[ J ]. Clin Cancer Res, 2007,13 ( 13 ) : 3942 - 3950.
  • 5Jain RK. Normalization of tumor vasculature: An emerging con- cept in antiangiogcnic therapy [ J ]. Science, 2005,307 ( 5706 ) : 58 - 62.

同被引文献59

  • 1张燕,左国庆,汤为学.奥沙利铂对人肝癌细胞株HepG2体外增殖的影响[J].中华肝脏病杂志,2004,12(6):374-375. 被引量:40
  • 2冯觉平,于世英,王亚萍,袁响林,李敏,方静.奥沙利铂对肝癌细胞HepG2生物学行为的影响[J].肿瘤,2010,30(9):753-757. 被引量:3
  • 3Shukui Qin,Yuxian Bai,Ho Yeong Lim,Sumitra Thongprasert,Yee Chao,Jia Fan,Tsai-Shen Yang,Vajarabhongsa Bhudhisawasdi,Won Ki Kang,Yu Zhou,Jee Hyun Lee,Yan Sun.Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia[J].Journal of Clinical Oncology.2013(28)
  • 4Peng Xiu,Xuesong Dong,Xiaofeng Dong,Zongzhen Xu,Huaqiang Zhu,Feng Liu,Zheng Wei,Bo Zhai,Jagat R. Kanwar,Hongchi Jiang,Jie Li,Xueying Sun.Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma[J].Cancer Sci.2013(3)
  • 5Olivier Mir,Romain Coriat,Pascaline Boudou-Rouquette,Stanislas Ropert,Jean-Philippe Durand,Anatole Cessot,Vincent Mallet,Philippe Sogni,Stanislas Chaussade,Stanislas Pol,Fran?ois Goldwasser.Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib[J].Medical Oncology.2012(4)
  • 6Alejandro Forner,Josep M Llovet,Jordi Bruix.Hepatocellular carcinoma[J].The Lancet.2012(9822)
  • 7Kai Qu,Xinsen Xu,Chang Liu,Qifei Wu,Jichao Wei,Fandi Meng,Lei Zhou,Zhixin Wang,Lei Lei,Peijun Liu.Negative regulation of transcription factor FoxM1 by p53 enhances oxaliplatin-induced senescence in hepatocellular carcinoma[J].Cancer Letters.2012
  • 8JunjiFuruse,TakujiOkusaka,ShuichiKaneko,MasatoshiKudo,KoheiNakachi,HidekiUeno,TatsuyaYamashita,KazuomiUeshima.Phase I/II study of the pharmacokinetics, safety and efficacy of S‐1 in patients with advanced hepatocellular carcinoma[J].Cancer Science.2010(12)
  • 9.Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy?[J].European Journal of Gastroenterology & Hepatology.2010(8)
  • 10刘和荣,周厚吾.生长抑素与奥沙利铂联合作用对HepG2增殖与凋亡的影响[J].中国社区医师(医学专业),2010,12(7):124-125. 被引量:2

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部